At a relative high dose (1 mg kg–1), our preliminary data showed that neither VSG22 nor DEX can effectively repress the airway hyper-responsiveness (AHR), a critical indicator of asthma in the mouse model; on the other hand, VSGC12 robustly repressed AHR to the basal level (Supplementary Figure S2). Here, AHR is linked to asthma.